imiquimod (Aldara)
Jump to navigation
Jump to search
Introduction
Tradename: Aldara.
Indications
- genital warts & other warts (only FDA approval[5])
- skin cancer
- vitiligo
- alopecia areata
- reduce recurrence of keloid scars[4]
- actinic keratosis[5][6][8][9]
- superficial infantile hemangiomas[10]
- vulvar intraepithelial neoplasia[11] Dosing:
- QHS or every other night to reduce skin irritation
- actinic keratosis:
- QHS 2-3 times/week for 4 months
- wash off after 8 hours
Pharmacokinetics
takes about 10 weeks for improvement
Adverse effects
- local skin reactions
- rash, erythema
- hypopigmentation
- pruritus
- erosions
- scabbing
- remote skin reaction
- bleeding
- pruritus
- pain
- Tinea cruris
- systemic
Mechanism of action
- an immune response modifier
- 80% histological cure rate for basal cell carcinoma[7]
- advantage over surgery is does NOT leave scar[7]
Notes
cost about $116/month (2004)[6]
More general terms
References
- ↑ 3M package insert
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Prescriber's Letter 7(2):10, Feb. 2000
- ↑ 4.0 4.1 Prescriber's Letter 8(5):29 2001
- ↑ 5.0 5.1 5.2 Prescriber's Letter 10(1):4 2003
- ↑ 6.0 6.1 6.2 Prescriber's Letter 11(5):27-28 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200507&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 7.0 7.1 7.2 7.3 Journal Watch 24(13):102, 2004 Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle- controlled studies. J Am Acad Dermatol. 2004 May;50(5):722-33. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15097956
- ↑ 8.0 8.1 Journal Watch 25(11):92, 2005 Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005 Apr;141(4):467-73. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15837864
- ↑ 9.0 9.1 Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006 Jun;126(6):1251-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16557235
- ↑ 10.0 10.1 Ho NTC et al Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol 2007, 56:63 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17190622
- ↑ 11.0 11.1 Deprecated Reference